文献速递糖尿病肥胖与代谢综合征

司美格鲁肽对超重或肥胖伴或不伴2型糖尿病患者白蛋白尿和肾功能的影响:STEP 1、2和3试验的探索性分析

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
PubMed 文献 · Diabetes Care · 2023-01-01

本文为STEP 1-3试验的事后分析,评估司美格鲁肽(最高2.4 mg)对肾功能的影响。STEP 2中司美格鲁肽1.0 mg和2.4 mg组第68周UACR分别降低14.8%和20.6%,安慰剂组升高18.3%;汇总STEP 1-3分析中司美格鲁肽2.4 mg与安慰剂组eGFR轨迹无差异。

要点

  • STEP 2中司美格鲁肽1.0 mg和2.4 mg组第68周UACR分别降低14.8%和20.6%,安慰剂组升高18.3%。
  • 司美格鲁肽1.0 mg和2.4 mg组UACR状态改善比例均高于安慰剂组(P=0.0004和P=0.0014)。
  • 汇总STEP 1-3分析中司美格鲁肽2.4 mg与安慰剂组第68周eGFR轨迹无差异。

核心结论

  • 司美格鲁肽改善了超重或肥胖伴2型糖尿病成人的UACR。
  • 在肾功能正常的参与者中,司美格鲁肽对eGFR下降无影响。

研究设计与样本

  • 本文为STEP 1-3试验(NCT03548935、NCT03552757、NCT03611582)的事后分析。
  • STEP 1-3纳入超重或肥胖成人,STEP 2患者还患有2型糖尿病。
  • 参与者每周一次皮下注射司美格鲁肽1.0 mg(仅STEP 2)、2.4 mg或安慰剂共68周,联合生活方式干预(STEP 1和2)或强化行为治疗(STEP 3)。
  • STEP 2评估从基线至第68周UACR和UACR状态的变化,汇总STEP 1-3数据评估eGFR变化。

主要发现

  • STEP 2中1,205例(占全部队列99.6%)患者有UACR数据,司美格鲁肽1.0 mg、2.4 mg和安慰剂组基线UACR几何均值分别为13.7、12.5和13.2 mg/g。
  • 第68周时,司美格鲁肽1.0 mg和2.4 mg组UACR分别变化-14.8%和-20.6%,安慰剂组变化+18.3%。
  • 与安慰剂组相比,司美格鲁肽1.0 mg组UACR差异为-28.0%(95%CI -37.3, -17.3,P<0.0001),司美格鲁肽2.4 mg组差异为-32.9%(95%CI -41.6, -23.0,P=0.003)。
  • 司美格鲁肽1.0 mg和2.4 mg组UACR状态改善的患者比例均高于安慰剂组(P=0.0004和P=0.0014)。
  • 汇总STEP 1-3分析中3,379例参与者有eGFR数据,司美格鲁肽2.4 mg与安慰剂组第68周eGFR轨迹无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: These post hoc analyses of the Semaglutide Treatment Effect in People with obesity (STEP) 1-3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the effects of semaglutide (up to 2.4 mg) on kidney function. RESEARCH DESIGN AND METHODS: STEP 1-3 included adults with overweight/obesity; STEP 2 patients also had type 2 diabetes. Participants received once-weekly subcutaneous semaglutide 1.0 mg (STEP 2 only), 2.4 mg, or placebo for 68 weeks, plus lifestyle intervention (STEP 1 and 2) or intensive behavioral therapy (STEP 3). Changes in urine albumin-to-creatinine ratio (UACR) and UACR status from baseline to week 68 were assessed for STEP 2. Changes in estimated glomerular filtration rate (eGFR) were assessed from pooled STEP 1-3 data. RESULTS: In STEP 2, 1,205 (99.6% total cohort) patients had UACR data; geometric mean baseline UACR was 13.7, 12.5, and 13.2 mg/g with semaglutide 1.0 mg, 2.4 mg, and placebo, respectively. At week 68, UACR changes were -14.8% and -20.6% with semaglutide 1.0 mg and 2.4 mg, respectively, and +18.3% with placebo (between-group differences [95% CI] vs. placebo: -28.0% [-37.3, -17.3], P < 0.0001 for semaglutide 1.0 mg; -32.9% [-41.6, -23.0], P = 0.003 for semaglutide 2.4 mg). UACR status improved in greater proportions of patients with semaglutide 1.0 mg and 2.4 mg versus placebo (P = 0.0004 and P = 0.0014, respectively). In the pooled STEP 1-3 analyses, 3,379 participants had eGFR data; there was no difference between semaglutide 2.4 mg and placebo in eGFR trajectories at week 68. CONCLUSIONS: Semaglutide improved UACR in adults with overweight/obesity and type 2 diabetes. In participants with normal kidney function, semaglutide did not have an effect on eGFR decline.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Apperloo E, Davies M, et al. Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes Care. 2023. PMID: 36801984. doi:10.2337/dc22-1889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。